SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-17-254443
Filing Date
2017-08-10
Accepted
2017-08-10 16:06:07
Documents
2
Group Members
MILLENNIUM PHARMACEUTICALS, INC.TAKEDA A/STAKEDA EUROPE HOLDINGS B.V.TAKEDA PHARMA A/STAKEDA PHARMACEUTICALS INTERNATIONAL AGTAKEDA PHARMACEUTICALS U.S.A., INC.

Document Format Files

Seq Description Document Type Size
1 SC 13D d441072dsc13d.htm SC 13D 188594
2 EX-99.6 d441072dex996.htm EX-99.6 13181
  Complete submission text file 0001193125-17-254443.txt   203566
Mailing Address 9301 AMBERGLEN BLVD SUITE 100 AUSTIN TX 78729
Business Address 9301 AMBERGLEN BLVD SUITE 100 AUSTIN TX 78729 512 896 1555
Molecular Templates, Inc. (Subject) CIK: 0001183765 (see all company filings)

IRS No.: 943409596 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-81377 | Film No.: 171021500
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1-1, DOSCHOMACHI 4-CHOME CHUO-KU, OSALCA 540-8645 M0 00000
Business Address 1-1, DOSCHOMACHI 4-CHOME CHUO-KU, OSALCA 540-8645 M0 00000
TAKEDA PHARMACEUTICAL CO LTD (Filed by) CIK: 0001395064 (see all company filings)

IRS No.: 000000000
Type: SC 13D